Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Should You Buy?

Key Points

• Pharvaris (NASDAQ:PHVS) experienced a trading volume increase of 21%, with approximately 280,322 shares traded, while its stock price settled at $21.89.
• Recent analyst ratings include a "sell" from Weiss Ratings and a raised "neutral" rating from Bank of America, with a consensus price target of $32.60.
• The company, focused on therapies for rare diseases, reported a quarterly loss of ($0.94) EPS, which was below analyst expectations.

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 280,322 shares traded hands during trading, an increase of 21% from the previous session's volume of 231,640 shares.The stock last traded at $21.89 and had previously closed at $21.98.

Analysts Set New Price Targets

PHVS has been the subject of several analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Pharvaris in a report on Wednesday, October 8th. Zacks Research raised shares of Pharvaris from a "strong sell" rating to a "hold" rating in a report on Monday, August 18th. Bank of America raised shares of Pharvaris from an "underperform" rating to a "neutral" rating and lifted their price target for the company from $16.00 to $27.00 in a report on Thursday, October 9th. Finally, JMP Securities cut their price target on shares of Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a report on Wednesday, August 13th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Pharvaris presently has a consensus rating of "Hold" and an average price target of $32.60.

Pharvaris Stock Performance

The firm's 50-day moving average price is $22.97 and its 200 day moving average price is $19.24. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -6.29 and a beta of -2.77.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.07). As a group, equities research analysts predict that Pharvaris N.V. will post -2.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in Pharvaris during the second quarter valued at approximately $57,000. JPMorgan Chase & Co. grew its holdings in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock valued at $59,000 after purchasing an additional 783 shares during the period. Legal & General Group Plc grew its holdings in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock valued at $203,000 after purchasing an additional 1,695 shares during the period. California State Teachers Retirement System grew its holdings in Pharvaris by 9.8% during the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company's stock valued at $247,000 after purchasing an additional 1,257 shares during the period. Finally, Palumbo Wealth Management LLC lifted its stake in Pharvaris by 38.0% in the first quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company's stock valued at $221,000 after buying an additional 3,881 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.